David Hwang is a pathologist at UHN and an Associate Professor in the Department of Laboratory Medicine & Pathobiology at the University of Toronto. He completed MD and PhD degrees at the University of Toronto, followed by residency training in Anatomical Pathology. Complementing his clinical practice in pulmonary pathology, his primary research focus is in pulmonary infectious disease. He is currently funded by the National Sanitarium Association to study bacterial community-wide gene expression and its role in antibiotic responses and resistance in the cystic fibrosis lung. He is a member of CIHR Emerging Teams investigating nanotechnology-enabled diagnosis and treatment (led by Dr. Gang Zheng, UHN) and engaged in metagenomic profiling of the cystic fibrosis lung (led by Dr. David Guttman, University of Toronto). In addition to research in pulmonary infections, Dr. Hwang is also involved in lung transplantation and repair research in collaboration with investigators of the Latner Thoracic Research Laboratories and with investigators from the Toronto Lung Transplant Program.
Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non-small-cell Lung Cancer.
Clin Lung Cancer. 2018 Dec 19;:
Microbiome networks and change-point analysis reveal key community changes associated with cystic fibrosis pulmonary exacerbations.
NPJ Biofilms Microbiomes. 2019;5:4
Penicillin binding protein 3 is a common adaptive target among Pseudomonas aeruginosa isolates from adult cystic fibrosis patients treated with β-lactams.
Int J Antimicrob Agents. 2019 Jan 18;:
A genome-wide association analysis reveals a potential role for recombination in the evolution of antimicrobial resistance in Burkholderia multivorans.
PLoS Pathog. 2018 Dec 07;14(12):e1007453
Spectrum of chronic lung allograft pathology in a mouse minor-mismatched orthotopic lung transplant model.
Am J Transplant. 2018 Oct 31;:
Methods Mol Biol. 2018;1849:243-266
The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.
Lung Cancer. 2018 Sep;123:22-29
Banff Lung Report: Current knowledge and future research perspectives for diagnosis and treatment of pulmonary antibody mediated rejection (AMR).
Am J Transplant. 2018 Jun 28;:
Inhibition of regulated necrosis attenuates receptor-interacting protein kinase 1-mediated ischemia-reperfusion injury after lung transplantation.
J Heart Lung Transplant. 2018 Apr 26;:
Oncotarget. 2018 Apr 27;9(32):22559-22570
Associate Professor, Department of Laboratory Medicine & Pathobiology, University of Toronto